Alumis Inc.
ALMS
Rank in Stocks
#10200
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.41
Market Cap
$830.25M
Change (1 day)
4.81%
Change (1 year)
182.57%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
P/B ratio for Alumis Inc. (ALMS)
P/B ratio as of October 2026 TTM: 0.49
According to Alumis Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.49. At the end of 2023 the company had a P/B ratio of 0.80.
P/B ratio history for Alumis Inc. from 2021 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 0.49 | -27.66% |
| 2024 | 0.68 | -14.79% |
| 2023 | 0.80 | -36.26% |
| 2022 | 1.25 | -114.32% |
| 2021 | -8.75 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 1,170.79% |
US
|
|
| 13.2547 | 2,594.59% |
US
|
|
| 4.208 | 755.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 1,156.84% |
NL
|
